STAT3 and non-small cell lung carcinoma: In other studies, siRNA-mediated STAT3 inhibition enhanced the sensitivity of A549 and SPC-A1 NSCLC cells to cisplatin by enhancing apoptosis in a caspase-3-dependent manner [33], while the small molecule STAT3 inhibitor BBI-608 re-sensitized chemo-resistant NSCLC cells to cisplatin and inhibited cell proliferation [70].